Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409789 | 1.00 | DUT (1.00) | DUT | |
| SCHEMBL1409468 | 1.00 | DUT (1.00) | DUT | |
| SCHEMBL1409517 | 0.93 | DUT (1.00) | DUT | |
| SCHEMBL1409515 | 0.93 | DUT (1.00) | DUT | |
| SCHEMBL12630226 | 0.90 | DUT (0.82) | DUT | |
| SCHEMBL1409480 | 0.90 | DUT (1.00) | DUT | |
| SCHEMBL1409485 | 0.90 | DUT (1.00) | DUT | |
| SCHEMBL1409792 | 0.89 | DUT (1.00) | DUT | |
| SCHEMBL1409790 | 0.89 | DUT (1.00) | DUT | |
| SCHEMBL21690562 | 0.88 | DUT (0.90) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-8530490-B2 | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530490-B2 | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2295414-B1 | URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2295414-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295414-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009147843-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | 大鵬薬品工業株式会社 (JP) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | UNG, DPYD, DUT | DUT 3/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | DUT 3/4885 |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | SNRPB2, SNRPA1, DUT | DUT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.